Correlation Between Time in Range and HbA1c in People with Type 2 Diabetes on Basal Insulin: Post Hoc Analysis of the SWITCH PRO Study
Open Access
- 11 March 2023
- journal article
- research article
- Published by Springer Nature in Diabetes Therapy
- Vol. 14 (5) , 915-924
Abstract
Introduction Use of continuous glucose monitoring (CGM) in people with diabetes may provide a more complete picture of glycemic control than glycated hemoglobin (HbA1c) measurements, which do not capture day-to-day fluctuations in blood glucose levels. The randomized, crossover, phase IV SWITCH PRO study assessed time in range (TIR), derived from CGM, following treatment with insulin degludec or insulin glargine U100 in patients with type 2 diabetes at risk for hypoglycemia. This post hoc analysis evaluated the relationship between TIR and HbA1c, following treatment intensification during the SWITCH PRO study. Methods Correlation between absolute values for TIR (assessed over 2-week intervals) and HbA1c, at baseline and at the end of maintenance period 1 (M1; week 18) or maintenance period 2 (M2; week 36), were assessed by linear regression and using the Spearman correlation coefficient (rs). These methods were also used to assess correlation between change in TIR and change in HbA1c from baseline to the end of M1, both in the full cohort and in subgroups stratified by baseline median HbA1c (≥ 7.5% [≥ 58.5 mmol/mol] or < 7.5% [< 58.5 mmol/mol]). Results A total of 419 participants were included in the analysis. A moderate inverse linear correlation was observed between TIR and HbA1c at baseline (rs −0.54), becoming stronger following treatment intensification during maintenance periods M1 (weeks 17–18: rs −0.59) and M2 (weeks 35–36: rs −0.60). Changes in TIR and HbA1c from baseline to end of M1 were also linearly inversely correlated in the full cohort (rs –0.40) and the subgroup with baseline HbA1c ≥ 7.5% (rs −0.43). This was less apparent in the subgroup with baseline HbA1c < 7.5% (rs −0.17) (p-interaction = 0.07). Conclusion Results from this post hoc analysis of data from SWITCH PRO, one of the first large interventional clinical studies to use TIR as the primary outcome, further support TIR as a valid clinical indicator of glycemic control. Trial registration: ClinicalTrials.gov identifier, NCT03687827.Keywords
Funding Information
- Novo Nordisk
This publication has 17 references indexed in Scilit:
- Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in RangeDiabetes Care, 2019
- A View Beyond HbA1c: Role of Continuous Glucose MonitoringDiabetes Therapy, 2019
- The Relationship of Hemoglobin A1C to Time-in-Range in Patients with DiabetesDiabetes Technology & Therapeutics, 2019
- The Relationships Between Time in Range, Hyperglycemia Metrics, and HbA1cJournal of Diabetes Science and Technology, 2019
- Validation of Time in Range as an Outcome Measure for Diabetes Clinical TrialsDiabetes Care, 2018
- Does Time-in-Range Matter? Perspectives From People With Diabetes on the Success of Current Therapies and the Drivers of Improved OutcomesClinical Diabetes, 2018
- Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 DiabetesJAMA, 2017
- Development of the Likelihood of Low Glucose (LLG) Algorithm for Evaluating Risk of HypoglycemiaJournal of Diabetes Science and Technology, 2014
- World Medical Association Declaration of HelsinkiJAMA, 2013
- Relationship between Clinical Markers of Glycemia and Glucose Excursion Evaluated by Continuous Glucose Monitoring (CGM).Endocrine Journal, 2010